We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
+28.76%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$361M
AUM Growth
+$55.4M
(+18%)
Cap. Flow
+$39.7M
Cap. Flow
% of AUM
10.98%
Top 10 Holdings %
Top 10 Hldgs %
40.07%
Holding
85
New
33
Increased
24
Reduced
13
Closed
13
Top Buys
| 1 |
MoonLake Immunotherapeutics
MLTX
|
+$11.9M |
| 2 |
TG Therapeutics
TGTX
|
+$9.16M |
| 3 |
APLS
Apellis Pharmaceuticals
APLS
|
+$8.29M |
| 4 |
Roivant Sciences
ROIV
|
+$7.55M |
| 5 |
Viridian Therapeutics
VRDN
|
+$6.3M |
Top Sells
| 1 |
AMAM
Ambrx Biopharma Inc
AMAM
|
+$6.76M |
| 2 |
argenx
ARGX
|
+$5.71M |
| 3 |
Krystal Biotech
KRYS
|
+$5M |
| 4 |
Structure Therapeutics
GPCR
|
+$3.16M |
| 5 |
ATXS
Astria Therapeutics
ATXS
|
+$2.74M |
Sector Composition
| 1 | Healthcare | 85.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $23.7M | 6.57% |
250,000
-50,000
| -17% | -$4.64M |
|
2
Axsome Therapeutics
AXSM
$11.8B
| $16.8M | 4.64% |
210,000
+45,000
| +27% | +$3.78M |
|
3
Sarepta Therapeutics
SRPT
$1.82B
| $16.2M | 4.48% |
125,000
+25,000
| +25% | +$3.06M |
|
4
Biohaven
BHVN
$2.32B
| $15.6M | 4.31% |
285,000
+10,000
| +4% | +$495K |
|
|
5
MoonLake Immunotherapeutics
MLTX
$1.64B
| $15.1M | 4.17% |
300,000
+220,000
| +275% | +$11.9M |
|
|
6
Roivant Sciences
ROIV
$24.8B
| $13.7M | 3.79% |
1,300,000
+700,000
| +117% | +$7.55M |
|
|
7
TG Therapeutics
TGTX
$8.4B
| $12.5M | 3.47% |
825,000
+575,000
| +230% | +$9.16M |
|
|
8
Viridian Therapeutics
VRDN
$1.99B
| $10.9M | 3.03% |
625,000
+325,000
| +108% | +$6.3M |
|
9
Tarsus Pharmaceuticals
TARS
$2.61B
| $10.9M | 3.02% |
300,000
| – | – |
|
10
Crinetics Pharmaceuticals
CRNX
$8.88B
| $9.36M | 2.59% |
200,000
+135,000
| +208% | +$5.28M |
|
11
Alnylam Pharmaceuticals
ALNY
$35.7B
| $8.97M | 2.48% |
60,000
+32,500
| +118% | +$5.42M |
|
|
SLNO
12
DELISTED
Soleno Therapeutics
SLNO
| $8.56M | 2.37% |
200,000
+87,615
| +78% | +$3.96M |
|
13
Savara
SVRA
$1.13B
| $7.97M | 2.21% |
1,600,000
+850,000
| +113% | +$4.11M |
|
|
APLS
14
DELISTED
Apellis Pharmaceuticals
APLS
| $7.64M | 2.12% |
+130,000
| New | +$8.29M |
|
15
Perspective Therapeutics
CATX
$341M
| $7.14M | 1.98% |
600,000
+440,000
| +275% | +$3.75M |
|
|
BPMC
16
DELISTED
Blueprint Medicines
BPMC
| $6.9M | 1.91% |
+72,761
| New | +$6.24M |
|
|
JBIO
17
Jade Biosciences
JBIO
$1.27B
| $6.65M | 1.84% |
6,429
+429
| +7% | +$328K |
|
18
CALL
Viking Therapeutics
VKTX
$4.31B
| $6.56M | 1.82% |
+80,000
| New | +$3.56M |
|
19
Vaxcyte
PCVX
$8.12B
| $6.49M | 1.8% |
95,000
+25,000
| +36% | +$1.73M |
|
20
Cabaletta Bio
CABA
$461M
| $6.4M | 1.77% |
375,000
+225,000
| +150% | +$4.83M |
|
|
21
Viking Therapeutics
VKTX
$4.31B
| $5.99M | 1.66% |
+73,002
| New | +$3.25M |
|
22
Rhythm Pharmaceuticals
RYTM
$7.31B
| $5.42M | 1.5% |
+125,000
| New | +$5.47M |
|
23
BridgeBio Pharma
BBIO
$15.9B
| $5.41M | 1.5% |
175,000
+50,000
| +40% | +$1.7M |
|
24
Replimune Group
REPL
$859M
| $5.31M | 1.47% |
650,000
+250,000
| +63% | +$2.05M |
|
25
CALL
Cytokinetics
CYTK
$10.9B
| $5.26M | 1.46% |
75,000
-5,000
| -6% | -$387K |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q1 2024 Portfolio in Review
As of Q1 2024, Ghost Tree Capital held 85 positions worth $361M, up 18% from $306M the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Ghost Tree Capital deployed $39.7M of net new capital in Q1 2024, opening 33 new positions and adding to 24 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 130,000 shares worth $7.64M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 56% a quarter earlier.
On the sell side, the largest reduction was Krystal Biotech, an estimated $5M trimmed.
- Ghost Tree Capital's largest Q1 2024 buy was Apellis Pharmaceuticals: 130,000 shares worth $7.64M.
- Ghost Tree Capital added most to MoonLake Immunotherapeutics in Q1 2024, an estimated $11.9M increase.
- Ghost Tree Capital's biggest Q1 2024 reduction was Krystal Biotech, cutting an estimated $5M.
- Ghost Tree Capital fully exited Ambrx Biopharma Inc in Q1 2024, selling an estimated $6.76M.
- Ghost Tree Capital's ten largest holdings make up 40% of its $361M portfolio in Q1 2024.
- Ghost Tree Capital opened 33 new positions and closed 13 in Q1 2024.
- Ghost Tree Capital's portfolio value rose 18% quarter-over-quarter to $361M.
Based on Ghost Tree Capital's 13F filing for Q1 2024, filed 15 May 2024.